Reportlinker.com

Reportlinker.com

June 25, 2008 14:18 ET

Examine the Monoclonal Antibodies Report: 2008 Update

Examine the Monoclonal Antibodies Report: 2008 Update - Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2013, evaluating the strategies companies are using to capitalize on

LONDON, UNITED KINGDOM--(Marketwire - June 25, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

Monoclonal Antibodies Report: 2008 Update - Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2013, evaluating the strategies companies are using to capitalize on

http://www.reportlinker.com/p090421/Monoclonal-Antibodies-Report-2008-Update---Detailed-analysis-of-the-monoclonal-antibody-segment-encompassing-market-dynamics-key-therapy-areas-technology-and-target-types-through-to-2013-evaluating-the-strategies-companies-are-using-to-capitalize-on.html

Introduction

The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2013 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.

Scope

Comprehensive financial strategic analysis of the mAb market out to 2013 Global sales forecasts to 2013 for marketed and Phase III mAb products Analysis of market trends by product, company, therapy area, technology and target type Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics

Highlights

The overall prescription pharmaceutical market is expected to face a decline in sales over 2011 to 2012 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth. Over the forecast period monoclonal antibodies are predicted to enjoy double-digit growth while small molecule drugs face declining growth rates. The main barrier to sales growth for small molecules is exposure to material generic competition, which will have no effect on mAbs out to 2013. mAbs currently command a three-fold average revenue per product premium over small molecules. Positive factors supporting this premium include a higher demand due to addressing therapy areas of high unmet need and lower competitive intensity due to accessing novel target space.

Reasons to Purchase

Assess the key products that will drive sales growth in the mAb market to 2013 Understand the challenges and barriers to entry for new players seeking to venture into the mAb market Understand the nature of the generic threat across different molecule types and the insulation of mAb products from biosimilars.

About the PharmaVitae team 3

Scope of the report 4

CHAPTER 1 EXECUTIVE SUMMARY 5

Key findings 5

Total market outlook 5

Monoclonal antibody market outlook 6

Summary of key changes made to mAb market forecast since 2007 report 8

Introduction to the PharmaVitae company universe 10

The prescription pharmaceutical market to 2012 13

Prescription pharmaceutical market performance, 2007-12 13

Balance of launches and expiries in the prescription pharmaceutical market, 2007-12 14

Forecast sales performance by molecule type 15

Small molecules 16

Therapeutic proteins 17

Monoclonal antibodies 17

Vaccines 17

Industry consequences of molecule type 18

Prescription pharmaceutical sales by molecule type, 2007-12 20

Changes in annual sales by molecule type 21

Sales growth rate by molecule type, 2007-13 22

Average revenue analysis 23

Monoclonal antibodies are the most attractive product segment in the prescription pharmaceutical market out to 2012 25

mAb market to 2013 28

mAb market performance, 2007-13 28

Product analysis (size) 29

Product analysis (growth) 31

The two key commercial mAb groups: The 'Big 5' and the 'Emerging 8' 32

The 'Big 5' mAbs 33

The 'Emerging 8' mAbs 35

Commercial dominance of the 'Big 5' and the 'Emerging 8' within the mAb segment 37

Company level sales growth 40

Therapy area level sales growth 42

Technology level sales growth 44

Target level sales growth 45

Scientific and market forces driving mAb success 46

Understanding the forces driving the commercial success of the 'Big 5' monoclonal antibodies 46

Each monoclonal antibody has achieved a first-to-market 'land grab' of a novel target 47

Subsequent horizontal market expansion 47

Ever-rising barriers to entry for competitor products 48

Idealized representation of 'Big 5' evolution 49

Case studies of 'Big 5' mAb commercial evolution 52

Tyrosine kinase domain provide a route to receptor targets 53

Summary - The 'mAb landscape' in 2013 57

How the mAb landscape map was created 57

Key feature 1 of the mAb landscape - the 'Big 5' mAbs 59

Key feature 2 of the mAb landscape - novel targets within the 'Emerging 8' 59

Key feature 3 of the mAb landscape - spanning multiple therapy areas 59

Key feature 4 of the mAb landscape - small molecule incursion 59

CHAPTER 2 MAB TECHNOLOGY OVERVIEW 64

Key findings 64

Introduction 65

The immune system 65

B lymphocytes and antibodies 65

Antibody structure 65

Hybridoma technique - the production of mAbs 67

Monoclonal antibodies as therapeutic agents 67

Targets 68

Target selection - the importance of an accessible epitope 68

Production of mAbs 69

Transgenic mice 69

Phage display 70

Future focus 70

Mode of action 71

mAb-focused oncology 71

The effect of the effector region 72

Blockade 72

mAbs as a delivery vehicle 72

Evolution of mAbs 73

Limitations associated with immunization 73

Murine 78

Chimeric and humanized antibodies 79

Chimeric 79

Humanized 80

Fully human 81

Fragments 81

Conjugated 84

Radiolabeled conjugated mAbs 84

Focus for antibody R&D - oncology immunotoxin drug conjugates 85

Naked mAbs still dominate 87

Systematic naming of monoclonal antibodies 88

The mAb timeline - technology evolution 89

Manufacturing 95

Time to market and manufacturing of monoclonal antibodies 95

Mammalian cell culture - still the most widely-used system 96

CHAPTER 3 MARKET ANALYSIS 99

Key findings 99

Introduction 100

mAb market: historical performance, 2001-07 100

mAb market: forecast performance, 2007-13 103

Product analysis 104

Historical product analysis, 2001-07 105

Historical product growth drivers 108

Remicade (infliximab) 108

Herceptin (trastuzumab) 109

Avastin (bevacizumab) 110

MabThera/Rituxan (rituximab) 110

Humira (adalimumab) 111

Forecast product analysis, 2007-13 112

Forecast product growth drivers 115

Avastin 115

Humira 117

Bapineuzumab 118

Denosumab 119

MabThera/Rituxan 120

Numax 121

Herceptin 122

Golimumab 123

Forecast product growth resistors 124

Remicade 124

Synagis 125

Company analysis 126

Historical company analysis, 2001-07 127

Historical company growth drivers 129

Genentech and Roche 129

Abbott Laboratories 133

Johnson & Johnson 133

Forecast company analysis, 2007-13 134

Forecast company growth drivers 137

Genentech and Roche 137

Abbott 138

Amgen 139

Elan & Wyeth 140

Therapy area analysis 141

Historical therapy area analysis, 2001-07 142

Historical therapy area growth drivers 144

Oncology 144

Immunology & inflammation 145

Forecast therapy area analysis, 2007-13 146

Forecast therapy area growth drivers 147

Oncology 147

Immunology & inflammation 149

Central nervous system 150

Musculoskeletal 150

Technology analysis 151

Historical technology analysis, 2001-07 152

Historical technology growth drivers 154

Humanized mAb 154

Chimeric mAb 154

Human mAb 154

Forecast technology analysis, 2007-13 155

Forecast technology growth drivers 157

Humanized mAb 157

Human mAb 157

Antibody fragment 158

Chimeric mAb 158

Target analysis 159

Historical target analysis, 2001-07 159

Historical target growth drivers 161

TNF alfa 161

VEGF 162

HER2 163

CD20 163

EGFR 163

Forecast target analysis, 2007-13 164

Forecast target growth drivers 166

VEGF 166

TNF alfa 167

Amyloid beta 167

CD20 168

RANKL 168

HER2 169

CHAPTER 4 PIPELINE ANALYSIS 170

Key findings 170

Introduction 171

mAb pipeline overview 172

Company pipeline analysis 178

Early-stage company pipeline analysis 184

Technology pipeline analysis 189

Human content of mAbs, the future focus 194

Therapy area pipeline analysis 195

Target pipeline analysis 198

Target crowding evident with the late-stage mAbs - with lifecycle management strategies being employed 199

Novel target early-stage candidates 202

Will further launches add to target crowding? 209

CD20 210

TNF alfa 211

HER2 and VEGF 212

CHAPTER 5 PRODUCT OVERVIEW 213

Key findings 213

Oncology 214

Avastin 214

Overview 214

Sales forecast 215

Rituxan/MabThera 216

Overview 216

Sales forecast 216

Herceptin 218

Overview 218

Sales forecast 218

Erbitux 220

Overview 220

Sales forecast 220

Vectibix 222

Overview 222

Sales forecast 222

Denosumab (oncology) 224

Overview 224

Sales forecast 224

Pertuzumab 227

Overview 227

Sales forecast 228

Lumiliximab 229

Overview 229

Sales forecast 229

Ipilimumab 231

Overview 231

Sales forecast 231

Humax CD20 233

Overview 233

Sales forecast 233

Galiximab 235

Overview 235

Sales forecast 236

Campath/MAB Campath 237

Overview 237

Sales forecast 237

Mylotarg 239

Overview 239

Sales forecast 239

Rencarex 241

Overview 241

Sales forecast 241

Removab 243

Overview 243

Sales forecast 243

Zevalin 245

Overview 245

Sales forecast 245

Humax CD4 247

Overview 247

Sales forecast 247

Bexxar 249

Overview 249

Sales forecast 249

Humax EGFR 251

Overview 251

Sales forecast 251

Inotuzumab ozogamicin 253

Overview 253

Sales forecast 253

Theraloc 255

Overview 255

Sales forecast 255

Abagovomab 257

Overview 257

Sales forecast 257

Proxinium/Vicinium 259

Overview 259

Sales forecast 259

Immunology & inflammation 261

Humira 261

Overview 261

Sales forecast 261

Remicade 264

Overview 264

Sales forecast 264

Golimumab 267

Overview 267

Sales forecast 267

Actemra 269

Overview 269

Sales forecast 269

Cimzia 271

Overview 271

Sales forecast 271

Ocrelizumab 273

Overview 273

Sales forecast 273

Soliris 275

Overview 275

Sales forecast 275

Ustekinumab 277

Overview 277

Sales forecast 277

Rituxan/MabThera RA 279

Overview 279

Sales forecast 279

Mepolizumab 281

Overview 281

Sales forecast 281

Raptiva 283

Overview 283

Sales forecast 283

Simulect 285

Overview 285

Sales forecast 285

Canakinumab 287

Overview 287

Sales forecast 287

Epratuzumab 289

Overview 289

Sales forecast 289

ABT-874 291

Overview 291

Sales forecast 291

Zenapax 293

Overview 293

Sales forecast 293

Belimumab 295

Overview 295

Sales forecast 295

Reslizumab 297

Overview 297

Sales forecast 297

CNS 299

Bapineuzumab 299

Overview 299

Sales forecast 300

Tysabri 302

Overview 302

Sales forecast 302

MabThera/Rituxan (CNS) 304

Overview 304

Sales forecast 304

Campath/MAB Campath (CNS) 306

Overview 306

Sales forecast 306

Other 308

Lucentis 308

Overview 308

Sales forecast 309

Infectious diseases 311

Numax 311

Overview 311

Sales forecast 311

Synagis 313

Overview 313

Sales forecast 313

Aurograb 315

Overview 315

Sales forecast 315

Mycograb 317

Overview 317

Sales forecast 317

Musculoskeletal 319

Denosumab 319

Overview 319

Sales forecast 319

Respiratory 321

Xolair 321

Overview 321

Sales forecast 322

Cardiovascular 324

ReoPro 324

Overview 324

Sales forecast 325

Endocrine, metabolic and genetic disorders 326

Teplizumab 326

Overview 326

Sales forecast 327

CHAPTER 6 APPENDIX 328

Case studies: 'Big 5' mAb commercial evolution 328

Commercial evolution of Rituxan (CD20 market) 329

Commercial evolution of Remicade and Humira (TNF alfa market) 332

Commercial evolution of Herceptin (HER2 market) 336

Commercial evolution of Avastin (VEGF market) 339

Commercial evolution of the EGFR market 344

References 346

Datamonitor reports 346

List of Tables

Table 1: Summary of key changes 8

Table 2: PharmaVitae company coverage by peer set 11

Table 3: Molecule type definitions 16

Table 4: General characteristics of small molecule drugs vs. biologics 18

Table 5: Prescription pharmaceutical sales ($m) by molecule type, 2007-12 20

Table 6: Average revenues by molecule type, 2007 23

Table 7: The 'Big 5' (annual revenues greater than $3 billion in both 2007 and 2013) 33

Table 8: The 'Emerging 8' ( greater than $500m growth 07-13) 35

Table 9: Overview of a selection of marketed mAbs: technology type and immunogenicity 75

Table 10: Infix nomenclature for mAbs 88

Table 11: Manufacturing cell lines for marketed mAbs 97

Table 12: Historical mAb product sales ($m), 2001-07 106

Table 13: Forecast mAb product sales ($m), 2007-13 112

Table 14: Historical mAb sales by company ($m), 2001-07 128

Table 15: Forecast mAb sales by company ($m), 2007-13 135

Table 16: Historical sales by therapy area ($m), 2001-07 143

Table 17: Forecast sales by therapy area ($m), 2007-13 146

Table 18: Historical sales by technology ($m), 2001-07 152

Table 19: Forecast sales by technology ($m), 2007-13 155

Table 20: Historical sales by target ($m), 2001-07 160

Table 21: Forecast sales by target ($m), 2007-13 165

Table 22: mAb pipeline overview 172

Table 23: Count of marketed mAbs 178

Table 24: Count of Phase III mAb players 181

Table 25: Count of companies with multiple Phase I-II mAb candidates 185

Table 26: mAb count split by technology type 189

Table 27: Count of mAb candidates by therapy area 195

Table 28: Detailed product/target analysis - late stage 198

Table 29: Novel late-stage targets 201

Table 30: Novel early-stage targets 203

Table 31: Companies with multiple novel early-stage targets 207

Table 32: The 'Big 5' targets and possible future entrants 209

Table 33: Avastin: overview 214

Table 34: Avastin global sales ($m), 2007-13 215

Table 35: Rituxan/MabThera: overview 216

Table 36: MabThera/Rituxan global sales ($m), 2007-13 216

Table 37: Herceptin: overview 218

Table 38: Herceptin global sales ($m), 2007-13 218

Table 39: Erbitux: overview 220

Table 40: Erbitux global sales ($m), 2007-13 220

Table 41: Vectibix: overview 222

Table 42: Vectibix global sales ($m), 2007-13 222

Table 43: Denosumab: overview 224

Table 44: Denosumab (oncology) global sales ($m), 2007-13 224

Table 45: Pertuzumab: overview 227

Table 46: Pertuzumab global sales ($m), 2007-13 228

Table 47: Lumiliximab: overview 229

Table 48: Lumiliximab global sales ($m), 2007-13 229

Table 49: Ipilimumab: overview 231

Table 50: Ipilimumab global sales ($m), 2007-13 231

Table 51: Humax CD20: overview 233

Table 52: Humax CD20 global sales ($m), 2007-13 233

Table 53: Galiximab: overview 235

Table 54: Galiximab global sales ($m), 2007-13 236

Table 55: MAB Campath: overview 237

Table 56: MAB Campath global sales ($m), 2007-13 237

Table 57: Mylotarg: overview 239

Table 58: Mylotarg global sales ($m), 2007-13 239

Table 59: Rencarex: overview 241

Table 60: Rencarex global sales ($m), 2007-13 241

Table 61: Removab: overview 243

Table 62: Removab global sales ($m), 2007-13 243

Table 63: Zevalin: overview 245

Table 64: Zevalin global sales ($m), 2007-13 245

Table 65: Humax CD4: overview 247

Table 66: Humax CD4 global sales ($m), 2007-13 247

Table 67: Bexxar: overview 249

Table 68: Bexxar global sales ($m), 2007-13 249

Table 69: Humax EGFR: overview 251

Table 70: Humax EGFR global sales ($m), 2007-13 251

Table 71: Inotuzumab ozogamicin: overview 253

Table 72: Inotuzumab ozogamicin global sales ($m), 2007-13 253

Table 73: Theraloc: overview 255

Table 74: Theraloc global sales ($m), 2007-13 255

Table 75: Abagovomab: overview 257

Table 76: Abagovomab global sales ($m), 2007-13 257

Table 77: Proxinium/Vicinium: overview 259

Table 78: Proxinium/Vicinium global sales ($m), 2007-13 259

Table 79: Humira: overview 261

Table 80: Humira global sales ($m), 2007-13 261

Table 81: Remicade: overview 264

Table 82: Remicade global sales ($m), 2007-13 264

Table 83: Golimumab: overview 267

Table 84: Golimumab global sales ($m), 2007-13 267

Table 85: Actemra: overview 269

Table 86: Actemra global sales ($m), 2007-13 269

Table 87: Cimzia: overview 271

Table 88: Cimzia global sales ($m), 2007-13 271

Table 89: Ocrelizumab: overview 273

Table 90: Ocrelizumab global sales ($m), 2007-13 273

Table 91: Soliris: overview 275

Table 92: Soliris global sales ($m), 2007-13 275

Table 93: Ustekinumab: overview 277

Table 94: Ustekinumab global sales ($m), 2007-13 277

Table 95: Rituxan/MabThera RA: overview 279

Table 96: MabThera/Rituxan RA global sales ($m), 2007-13 279

Table 97: Mepolizumab: overview 281

Table 98: Mepolizumab global sales ($m), 2007-13 281

Table 99: Raptiva: overview 283

Table 100: Raptiva global sales ($m), 2007-13 283

Table 101: Simulect: overview 285

Table 102: Simulect global sales ($m), 2007-13 285

Table 103: Canakinumab: overview 287

Table 104: Canakinumab global sales ($m), 2007-13 287

Table 105: Epratuzumab: overview 289

Table 106: Epratuzumab global sales ($m), 2007-13 289

Table 107: ABT-874: overview 291

Table 108: ABT-874 global sales ($m), 2007-13 291

Table 109: Zenapax: overview 293

Table 110: Zenapax global sales ($m), 2007-13 293

Table 111: Belimumab: overview 295

Table 112: Belimumab global sales ($m), 2007-13 295

Table 113: Reslizumab: overview 297

Table 114: Reslizumab global sales ($m), 2007-13 297

Table 115: Bapineuzumab: overview 299

Table 116: Bapineuzumab global sales ($m), 2007-13 300

Table 117: Tysabri: overview 302

Table 118: Tysabri global sales ($m), 2007-13 302

Table 119: MabThera/Rituxan (CNS): overview 304

Table 120: MabThera/Rituxan (CNS) global sales ($m), 2007-13 304

Table 121: MAB Campath (CNS): overview 306

Table 122: MAB Campath global sales ($m), 2007-13 306

Table 123: Lucentis: overview 308

Table 124: Lucentis global sales ($m), 2007-13 309

Table 125: Numax: overview 311

Table 126: Numax global sales ($m), 2007-13 311

Table 127: Synagis: overview 313

Table 128: Synagis global sales ($m), 2007-13 313

Table 129: Aurograb: overview 315

Table 130: Aurograb global sales ($m), 2007-13 315

Table 131: Mycograb: overview 317

Table 132: Mycograb global sales ($m), 2007-13 317

Table 133: Denosumab: overview 319

Table 134: Denosumab global sales ($m), 2007-13 319

Table 135: Xolair: overview 321

Table 136: Xolair global sales ($m), 2007-13 322

Table 137: ReoPro: overview 324

Table 138: ReoPro global sales ($m), 2007-13 325

Table 139: Teplizumab: overview 326

Table 140: Teplizumab global sales ($m), 2007-13 327

Table 141: Remicade vs. Enbrel key approvals 333

Table 142: Remicade vs. Enbrel key approvals 334

Table 143: The VEGF ligand and receptor targeting therapeutics 341

List of Figures

Figure 1: Updated mAb market forecast ($m), 2007-13 9

Figure 2: The total pharmaceutical market outlook, sales ($m) and year-on-year growth rate (%), 2001-13 13

Figure 3: Balance of launches and expiries in the prescription pharmaceutical market ($m), 2007-12 14

Figure 4: Absolute growth ($m) of PharmaVitae universe by molecule type 21

Figure 5: 2007-13 CAGRs of PharmaVitae universe by molecule type 22

Figure 6: Average revenue analysis by molecule type ($m), 2007 24

Figure 7: Sales growth drivers and resistors for mAbs, therapeutic proteins and small molecules 26

Figure 8: mAb market outlook, sales ($m) and year-on-year growth (%), 2007-13 28

Figure 9: Product analysis, historical and forecast sales growth ($m), 2001-13 29

Figure 10: Key mAb growth drivers & resistors ($m), 2007-13 31

Figure 11: Total market ($m) from the 'Big 5', 'Emerging 8' and others, 2001-13 37

Figure 12: Total market growth ($m) from the 'Big 5', 'Emerging 8' and others, 2007-13 38

Figure 13: Percentage contribution to sales from the 'Big 5' and 'Emerging 8' in 2007 and 2013 39

Figure 14: Company analysis, historical and forecast sales growth ($m), 2001-13 40

Figure 15: Therapy area analysis, historical and forecast sales growth ($m), 2001-13 42

Figure 16: Technology analysis, historical and forecast sales growth ($m), 2001-13 44

Figure 17: Target analysis, historical and forecast sales growth ($m), 2001-13 45

Figure 18: Idealized mAb model 51

Figure 19: Protein domain structures of key receptor/ligand pairs in the mAb market 55

Figure 20: Conceptual map of the commercial mAb landscape in 2013 58

Figure 21: The structure of an antibody 66

Figure 22: Types of antibodies 74

Figure 23: Immunogenicity ranges 76

Figure 24: Number of marketed mAb technologies 77

Figure 25: Schematic illustration of antibody fragments 83

Figure 26: Number of marketed full length mAbs versus fragments 84

Figure 27: Number of marketed naked and conjugated mAbs 87

Figure 28: mAb timeline - technology shift 90

Figure 29: The monoclonal antibody market, 2001-07 102

Figure 30: The monoclonal antibody market, 2007-13 103

Figure 31: mAb product sales ($m) 2001-13 104

Figure 32: Growth driver/resistor products of historical revenue performance ($m), 2001-07 108

Figure 33: Growth driver/resistor products of forecast revenue performance ($m), 2007-13 115

Figure 34: mAb company sales ($m), 2001-13 126

Figure 35: Growth driver/resistor companies of historical revenue performance ($m), 2001-07 129

Figure 36: Growth driver/resistor companies of forecast revenue performance ($m), 2007-13 137

Figure 37: mAb therapy area sales ($m) 2001-13 141

Figure 38: Growth driver/resistor therapy areas of historical revenue performance ($m), 2001-07 144

Figure 39: Growth driver/resistor therapy areas of forecast revenue performance ($m), 2007-13 147

Figure 40: mAb technology sales ($m), 2001-13 151

Figure 41: Growth driver/resistor technologies of historical revenue performance ($m), 2001-07 153

Figure 42: Growth driver/resistor technologies of historical revenue performance ($m), 2007-13 156

Figure 43: mAb target sales ($m), 2001-13 159

Figure 44: Growth driver/resistor targets of historical revenue performance ($m), 2001-07 161

Figure 45: Growth driver/resistor targets of forecast revenue performance ($m), 2007-13 166

Figure 46: Count of marketed mAb players 179

Figure 47: Count of Phase III pipeline mAb players 182

Figure 48: Count of companies with multiple Phase I-II mAb candidates 186

Figure 49: Phase I-III pipeline count split by technology 190

Figure 50: The stepwise evolution of naked mAb technology 191

Figure 51: Overview of pipeline technology type Phase I-registration 192

Figure 52: Emerging mAb technologies (% mAb candidates) 194

Figure 53: Phase I-pre-reg mAb count split by therapy area 196

Figure 54: Count of the most popular targets in early-stage development 206

Figure 55: Commercial evolution of the CD20 market 329

Figure 56: Commercial evolution of the TNF alfa market 332

Figure 57: Commercial evolution of the HER2 market 336

Figure 58: Commercial evolution of the VEGF/VEGFR market 339

Figure 59: Commercial evolution of the EGFR market 344

To order this report:

Monoclonal Antibodies Report: 2008 Update - Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2013, evaluating the strategies companies are using to capitalize on

http://www.reportlinker.com/p090421/Monoclonal-Antibodies-Report-2008-Update---Detailed-analysis-of-the-monoclonal-antibody-segment-encompassing-market-dynamics-key-therapy-areas-technology-and-target-types-through-to-2013-evaluating-the-strategies-companies-are-using-to-capitalize-on.html

More market research reports here!

Contact Information